Nebivolol in High-Risk, Obese African Americans With Stage 1 Hypertension: Effects on Blood Pressure, Vascular Compliance, and Endothelial Function

• Type of Material: Article
• Authors: Nadya Merchant, Emory University; Charles Searles Jr, Emory University; Anbu Pandian, Emory University; Syed T. Rahman, Emory University; Keith C. Ferdinand, Emory University; Guillermo Umpierrez, Emory University; Bobby V. Khan, Emory University
• Language: English
• Date: 2009-12-01
• Publisher: Wiley: 12 months
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2009 Wiley Periodicals, Inc.
• Final Published Version (URL): http://dx.doi.org/10.1111/j.1751-7176.2009.00198.x
• Title of Journal or Parent Work: Journal of Clinical Hypertension
• ISSN: 1524-6175
• Volume: 11
• Issue: 12
• Start Page: 720
• End Page: 725
• Grant/Funding Information: This study was supported by the National Institutes of Health grant (DK- R03DK073190).; Also, the investigators of the study received an unrestricted grant and the study drug (nebivolol) from Forest Pharmaceuticals.
• Keywords: Peripheral Vascular Disease; EFFICACY; Science & Technology; AWARENESS; Cardiovascular System & Cardiology; DOUBLE-BLIND; SUPEROXIDE DISMUTASE; PREVALENCE; Life Sciences & Biomedicine; DISEASE 2000; GLOBAL BURDEN; METABOLIC-SYNDROME; HEALTH; UNITED-STATES ADULTS
• Research Categories: Health Sciences, Pathology; Health Sciences, Medicine and Surgery

Abstract

The authors sought to determine whether nebivolol treatment results in changes in blood pressure (BP), nitric oxide bioavailability, and vascular function in obese African Americans with recently diagnosed stage 1 hypertension. Forty-three obese, hypertensive African Americans (mean BP: systolic, 148.8±14.3 mm Hg; diastolic, 90.4±8.2 mm Hg) were treated with nebivolol (5-10 mg/d) for 8 weeks. Primary outcomes were change in systolic and diastolic BP and efficacy in reaching normotensive BP. Mean systolic BP decreased by 9.2±14 mm Hg (P<.005) and diastolic BP decreased 6.8±9 mm Hg (P<.005) with 8 weeks of therapy. Significant improvements were seen in arterial compliance with nebivolol treatment as measured by aortic augmentation index (P<.005) and time to wave reflection (P=.013). Nebivolol treatment improved endothelial function as measured by flow-mediated dilation (P<.005). Levels of erythrocyte cellular superoxide dismutase increased with nebivolol, indirectly suggesting increased bioavailability of nitric oxide (P<.005). Monotherapy with nebivolol in obese, hypertensive African Americans results in significant systolic and diastolic BP reduction by mechanisms that include improved vascular function and compliance.